ResMed (RMD) Tops Q2 EPS by 1c
ResMed (NYSE: RMD) reported Q2 EPS of $0.37, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $306 million versus the consensus estimate of $307.6 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Downgrades ResMed (RMD) to Underperform
- ResMed Awarded Group Purchasing Contract with Premier
- EXFO, Inc. (EXFO) Misses Q3 EPS by 4c; Issues Light Q4 Outlook
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!